Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Company Overview - Vertex Pharmaceuticals Incorporated (VRTX) has a market cap of $116.9 billion and focuses on developing innovative therapies, particularly for cystic fibrosis with products like TRIKAFTA/KAFTRIO, ALYFTREK, and KALYDECO [1] - The company is also advancing treatments for serious diseases such as sickle cell disease, beta thalassemia, diabetes, kidney disease, and acute pain through a robust research pipeline and strategic collaborations [1] Financial Performance - Analysts expect VRTX to report an adjusted EPS of $4.41 for fiscal Q4 2025, representing a 24.6% increase from $3.54 in the same quarter last year [2] - For fiscal 2025, the projected adjusted EPS is $16.10, a significant recovery from a loss of $1.35 per share in fiscal 2024 [3] - In Q3 2025, Vertex reported total revenue of $3.08 billion, an 11% year-over-year increase, driven by growth in its cystic fibrosis franchise and contributions from new products CASGEVY and JOURNAVX [5] - The company has refined its full-year 2025 revenue guidance to between $11.9 billion and $12 billion, supported by expanding global launches and rising U.S. demand [5] Stock Performance - Over the past 52 weeks, shares of Vertex Pharmaceuticals have increased by 11.8%, which is below the S&P 500 Index's gain of 19.7% but slightly above the State Street Health Care Select Sector SPDR ETF's return of 11.3% [4] - The consensus rating for VRTX stock is "Moderate Buy," with 20 out of 32 analysts recommending a "Strong Buy," one a "Moderate Buy," 10 a "Hold," and one a "Strong Sell" [6] - The average analyst price target for Vertex Pharmaceuticals is $495.76, indicating a potential upside of 7.6% from current levels [6]